Drug Information

Drug General Information
Drug ID
D08JIP
Former ID
DNCL002518
Drug Name
Rintatolimod
Drug Type
siRNA drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Phase 3 [524780]
Company
Hemispherx Biopharma
CAS Number
CAS 38640-92-5
Target and Pathway
Target(s) Toll-like receptor 3 Target Info [531850]
KEGG Pathway Toll-like receptor signaling pathway
Hepatitis C
Hepatitis B
Influenza A
Herpes simplex infection
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Toll receptor signaling pathway
Pathway Interaction Database Endogenous TLR signaling
Reactome Ligand-dependent caspase activation
MyD88-independent TLR3/TLR4 cascade
Trafficking and processing of endosomal TLR
RIP-mediated NFkB activation via ZBP1
TRIF-mediated programmed cell death
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
IKK complex recruitment mediated by RIP1
TRAF6 mediated induction of TAK1 complex
WikiPathways Toll-like receptor signaling pathway
Cytosolic sensors of pathogen-associated DNA
Toll-Like Receptors Cascades
MyD88-independent cascade
Trafficking and processing of endosomal TLR
Regulation of toll-like receptor signaling pathway
References
Ref 524780ClinicalTrials.gov (NCT02151448) alphaDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies. U.S. National Institutes of Health.
Ref 531850A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.